@article{7ec368d2875c4a4ab61446545d8d8864,
title = "Targeted Therapeutics for Transthyretin Cardiac Amyloidosis: Proof That Precision Medicine in Heart Failure Is a Possibility?",
keywords = "Editorials, amyloidosis, heart failure, precision medicine",
author = "Shah, {Sanjiv J.}",
note = "Funding Information: Dr Shah is supported by grants from the National Institutes of Health (R01 HL140731, R01 HL120728, and R01 HL107577) and the American Heart Association (16SFRN28780016 and 15CVGPSD27260148) and by Actelion, Astra-Zeneca, Corvia, and Novartis; and has received consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Cardiora, Eisai, Ionis, Ironwood, Merck, Novartis, Pfizer, Sanofi, and United Therapeutics.",
year = "2019",
month = jan,
day = "22",
doi = "10.1161/CIRCULATIONAHA.118.037593",
language = "English (US)",
volume = "139",
pages = "444--447",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "4",
}